FARMINGTON, Conn., May 30, 2012 /PRNewswire-iReach/ -- Global Information Inc is pleased to announce the immediate availability of two new market research reports from Greystone Research Associates examining the markets for Transmucosal Drug Delivery and Systemic Nasal Sprays. (Photo: http://photos.prnewswire.com/prnh/20120530/CG15754) Oral Transmucosal Drug Delivery MarketGreystone Research Associates' new market study "Oral Transmucosal Drug Delivery: Products, Players, Markets and Forecasts" is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The report offers a detailed understanding of the products, markets and commercial opportunities for drug delivery films, sprays, lozenges, wafers and orally dissolvable tablets that are designed to be administered into the oral cavity and be absorbed systematically via the oral mucosa. The permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism. On the provider side, the development of alternative methods of drug administration has improved the ability of physicians to manage specific problems. Practitioners now recognize the rapid onset, relative reliability, and the general lack of patient … Continue reading →

Gordon Wiltsie / Getty Images A compound found in marijuana can treat schizophrenia as effectively as antipsychotic medications, with far fewer side effects, according to a preliminary clinical trial. Researchers led by Markus Leweke of the University of Cologne in Germany studied 39 people with schizophrenia who were hospitalized for a psychotic episode. Nineteen patients were treated with amisulpride, an antipsychotic medication that is not approved in the U.S., but is comparable to other medications that are. The rest of the patients were given cannabidiol (CBD), a substance found in marijuana that is thought to be responsible for some of its mellowing or anxiety-reducing effects. Unlike the main ingredient in marijuana, THC, which can produce psychotic reactions and may worsen schizophrenia, CBD has antipsychotic effects, according to previous research in both animals and humans. Neither the patients nor the scientists knew who was getting which drug. At the end of the four-week trial, both groups showed significant clinical improvement in their schizophrenic symptoms, and there was no difference between those getting CBD or amisulpride. (MORE: The Complex Link Between Marijuana and Schizophrenia) The results were amazing, says Daniel Piomelli, professor of pharmacology at the University of California-Irvine and a co-author … Continue reading →

Posted by Shezad Malik MD JDMay 30, 2012 1:09 PM According to medical experts, NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) users are prone to serious and life-threatening NuvaRing blood clots, known as venous thromboembolism, and other dangerous NuvaRing side effects. Recently medical studies, by the U.S. Food & Drug Administration (FDA) and the British Medical Journal, have found that NuvaRing raises the risk of deadly blood clots. The studies demonstrated that NuvaRing increased deep vein thrombosis and pulmonary embolism, when compared to older hormonal birth control pills. NuvaRing side effects include: Deep vein thrombosis Pulmonary embolism Heart attacks Strokes Wrongful death What is NuvaRing? NuvaRing is a hormonal contraceptive device that releases a combination of etonogestrel, a synthetic third generation progestin, and the estrogen, ethinyl estradiol. Merck & Co.s Organon subsidiary, released NuvaRing in 2001. NuvaRing is a small flexible ring that is designed to be inserted into the vagina once a month. NuvaRing prevents pregnancy by releasing controlled amounts of those hormones into the bloodstream. FDA October 2011 Study Continued here: Nuvaring Pulmonary Embolism and Deep Vein Thrombosis Risks … Continue reading →